Rational development of a cytotoxic peptide to trigger cell death

Molecular Pharmaceutics

Volumn 9, Issue 7, 2012, Pages 2080-2093

  Boohaker, Rebecca J ^a   Zhang, Ge ^a   Lee, Michael W ^a   Nemec, Kathleen N ^a   Santra, Santimukul ^b   Perez, J Manuel ^b   Khaled, Annette R ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

lipid membranes; metabolism; mitochondria; nanoparticles; necrosis

Indexed keywords

CALCEIN; CISPLATIN; CT20P; CYTOTOXIC AGENT; EFFECTOR CASPASE; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG EFFICACY; DRUG TARGETING; HYDROPHOBICITY; IN VITRO STUDY; LIPID MEMBRANE; LIPID VESICLE; MEMBRANE RUPTURE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CASPASES; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; CISPLATIN; HCT116 CELLS; HEK293 CELLS; HUMANS; MCF-7 CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MITOCHONDRIA; NANOPARTICLES; PEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84863315739     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300167e     Document Type: Article

References (42)

1. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-681
2. Oltvai, Z. N.; Milliman, C. L.; Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death Cell 1993, 74, 609-619
3. Elkholi, R.; Floros, K. V.; Chipuk, J. E. The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment Genes Cancer 2011, 2, 523-537
4. Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death Physiol. Rev. 2007, 87, 99-163
5. Sturm, I.; Bosanquet, A. G.; Hermann, S.; Guner, D.; Dorken, B.; Daniel, P. T. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy Cell Death Differ. 2003, 10, 477-484
6. Kuhar, M.; Sen, S.; Singh, N. Role of mitochondria in quercetin-enhanced chemotherapeutic response in human non-small cell lung carcinoma H-520 cells Anticancer Res. 2006, 26, 1297-1303
7. Castoreno, A. B.; Eggert, U. S. Small molecule probes of cellular pathways and networks ACS Chem. Biol. 2011, 6, 86-94
8. Pillarisetti, S. Are peptides the future? Small molecule versus peptides Curr. Pharm. Biotechnol. 2006, 7, 225-227
9. Wilson, W. H.; O'Connor, O. A.; Czuczman, M. S.; LaCasce, A. S.; Gerecitano, J. F.; Leonard, J. P.; Tulpule, A.; Dunleavy, K.; Xiong, H.; Chiu, Y. L.; Cui, Y.; Busman, T.; Elmore, S. W.; Rosenberg, S. H.; Krivoshik, A. P.; Enschede, S. H.; Humerickhouse, R. A. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Lancet Oncol. 2010, 11, 1149-1159
10. Roberts, A. W.; Seymour, J. F.; Brown, J. R.; Wierda, W. G.; Kipps, T. J.; Khaw, S. L.; Carney, D. A.; He, S. Z.; Huang, D. C.; Xiong, H.; Cui, Y.; Busman, T. A.; McKeegan, E. M.; Krivoshik, A. P.; Enschede, S. H.; Humerickhouse, R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease J. Clin. Oncol. 2012, 30, 488-496
11. Mason, K. D.; Khaw, S. L.; Rayeroux, K. C.; Chew, E.; Lee, E. F.; Fairlie, W. D.; Grigg, A. P.; Seymour, J. F.; Szer, J.; Huang, D. C.; Roberts, A. W. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia Leukemia 2009, 23, 2034-2041
12. Boohaker, R.; Lee, M. W.; Vishnubhotla, P.; Perez, J. M.; Khaled, A. R. The Use of Therapeutics Peptides to Target and to Kill Cancer Cells. Curr. Med. Chem. 2012, (Molecular Tools in Cancer Diagnosis and Therapy), in press.
13. Zhang, L.; Yu, J.; Park, B. H.; Kinzler, K. W.; Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents Science 2000, 290, 989-992
14. Boohaker, R. J.; Zhang, G.; Carlson, A. L.; Nemec, K. N.; Khaled, A. R. BAX supports the mitochondrial network, promoting bioenergetics in nonapoptotic cells Am. J. Physiol. 2011, 300, C1466-C1478
15. Santra, S.; Kaittanis, C.; Perez, J. M. Aliphatic hyperbranched polyester: a new building block in the construction of multifunctional nanoparticles and nanocomposites Langmuir 2010, 26, 5364-5373
16. Hoskin, D. W.; Ramamoorthy, A. Studies on anticancer activities of antimicrobial peptides Biochim. Biophys. Acta 2008, 1778, 357-375
17. Gray, M. W. The endosymbiont hypothesis revisited Int. Rev. Cytol. 1992, 141, 233-357
18. Morden, C. W.; Delwiche, C. F.; Kuhsel, M.; Palmer, J. D. Gene phylogenies and the endosymbiotic origin of plastids Biosystems 1992, 28, 75-90
19. Ellerby, H. M.; Arap, W.; Ellerby, L. M.; Kain, R.; Andrusiak, R.; Rio, G. D.; Krajewski, S.; Lombardo, C. R.; Rao, R.; Ruoslahti, E.; Bredesen, D. E.; Pasqualini, R. Anti-cancer activity of targeted pro-apoptotic peptides Nat. Med. 1999, 5, 1032-1038
20. Law, B.; Quinti, L.; Choi, Y.; Weissleder, R.; Tung, C. H. A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity Mol. Cancer Ther. 2006, 5, 1944-1949
21. Agemy, L.; Friedmann-Morvinski, D.; Kotamraju, V. R.; Roth, L.; Sugahara, K. N.; Girard, O. M.; Mattrey, R. F.; Verma, I. M.; Ruoslahti, E. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 17450-17455
22. Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix Science 2004, 305, 1466-1470
23. Valero, J. G.; Sancey, L.; Kucharczak, J.; Guillemin, Y.; Gimenez, D.; Prudent, J.; Gillet, G.; Salgado, J.; Coll, J. L.; Aouacheria, A. Bax-derived membrane-active peptides act as potent and direct inducers of apoptosis in cancer cells J. Cell Sci. 2011, 124, 556-564
24. Li, Y.; Pei, Y.; Zhang, X.; Gu, Z.; Zhou, Z.; Yuan, W.; Zhou, J.; Zhu, J.; Gao, X. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats J. Controlled Release 2001, 71, 203-211
25. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharmaceutics 2008, 5, 505-515
26. Berghe, T. V.; Vanlangenakker, N.; Parthoens, E.; Deckers, W.; Devos, M.; Festjens, N.; Guerin, C. J.; Brunk, U. T.; Declercq, W.; Vandenabeele, P. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features Cell Death Differ. 2010, 17, 922-930
27. Basanez, G.; Sharpe, J. C.; Galanis, J.; Brandt, T. B.; Hardwick, J. M.; Zimmerberg, J. Bax-type apoptotic proteins porate pure lipid bilayers through a mechanism sensitive to intrinsic monolayer curvature J. Biol. Chem. 2002, 277, 49360-49365
28. Garcia-Saez, A. J.; Mingarro, I.; Perez-Paya, E.; Salgado, J. Membrane-insertion fragments of Bcl-xL, Bax, and Bid Biochemistry 2004, 43, 10930-10943
29. Schlesinger, P. H.; Saito, M. The Bax pore in liposomes, Biophysics Cell Death Differ. 2006, 13, 1403-1408
30. Garcia-Saez, A. J.; Coraiola, M.; Serra, M. D.; Mingarro, I.; Muller, P.; Salgado, J. Peptides corresponding to helices 5 and 6 of Bax can independently form large lipid pores FEBS J. 2006, 273, 971-981
31. Garcia-Saez, A. J.; Coraiola, M.; Dalla, S. M.; Mingarro, I.; Menestrina, G.; Salgado, J. Peptides derived from apoptotic Bax and Bid reproduce the poration activity of the parent full-length proteins Biophys. J. 2005, 88, 3976-3990
32. Moreau, C.; Cartron, P. F.; Hunt, A.; Meflah, K.; Green, D. R.; Evan, G.; Vallette, F. M.; Juin, P. Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins J. Biol. Chem. 2003, 278, 19426-19435
33. Zhang, L.; Ming, L.; Yu, J. BH3 mimetics to improve cancer therapy; mechanisms and examples Drug Resist. Updates 2007, 10, 207-217
34. Riedl, S.; Rinner, B.; Asslaber, M.; Schaider, H.; Walzer, S.; Novak, A.; Lohner, K.; Zweytick, D. In search of a novel target-phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy Biochim. Biophys. Acta 2011, 1808, 2638-2645
35. Bafna, S.; Kaur, S.; Batra, S. K. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells Oncogene 2010, 29, 2893-2904
36. Fadnes, B.; Rekdal, O.; Uhlin-Hansen, L. The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells BMC Cancer 2009, 9, 183
37. viel-Ronen, S.; Lau, S. K.; Pintilie, M.; Lau, D.; Liu, N.; Tsao, M. S.; Jothy, S. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma Mod. Pathol. 2008, 21, 817-825
38. Javadpour, M. M.; Juban, M. M.; Lo, W. C.; Bishop, S. M.; Alberty, J. B.; Cowell, S. M.; Becker, C. L.; McLaughlin, M. L. De novo antimicrobial peptides with low mammalian cell toxicity J. Med. Chem. 1996, 39, 3107-3113
39. Mai, J. C.; Mi, Z.; Kim, S. H.; Ng, B.; Robbins, P. D. A proapoptotic peptide for the treatment of solid tumors Cancer Res. 2001, 61, 7709-7712
40. Kolevzon, N.; Kuflik, U.; Shmuel, M.; Benhamron, S.; Ringel, I.; Yavin, E. Multiple triphenylphosphonium cations as a platform for the delivery of a pro-apoptotic peptide Pharm. Res. 2011, 28, 2780-2789
41. Rege, K.; Patel, S. J.; Megeed, Z.; Yarmush, M. L. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells Cancer Res. 2007, 67, 6368-6375
42. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 1986, 46, 6387-6392